康臣药业集团有限公司（股票代码：01681）于2026年6月25日发布公告，披露当日于香港联合交易所场内回购普通股90,000股，约占该次回购前现有已发行股份0.0107%。回购价格介乎每股12.81港元至12.85港元，合计耗资约1,155,040港元（折合约115.50万港元）。
截至本次变动后，康臣药业集团有限公司已发行股份数为839,268,111股，库存股份数为2,279,000股，总股份数仍为841,547,111股。公告同时显示，本次回购的股份将作为库存股份持有。公司于2026年5月26日通过股份购回授权，授权购回上限为84,120,311股。截至此次回购前，根据购回授权已在交易所及其他证券交易所合计回购股份1,935,000股，占购回授权通过当日已发行股份总数的2.3003%。
公司在公告中确认，已遵守香港联合交易所有限公司证券上市规则及其他相关法律与监管规定。本次公告由公司秘书高海恩签署。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.